Verification evidence is still being completed.
PDF / print export
Calliditas Therapeutics
Stockholm, Sweden
- Verified lead
- Renee Aguiar-Lucander
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO
- 2026 technical specialization
- Orphan Diseases, Renal Disease, Hepatic Disease, Specialty Pharma, and Clinical Development
- Review cycle
- May 2026
- Full address
- Calliditas Therapeutics AB, D5, Kungsbron 1, SE-111 22 Stockholm, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Calliditas contact page confirming the Stockholm office address.
- Editorial note
- Calliditas Therapeutics is published because official company materials confirm current leadership, Stockholm operating address, and a real orphan-disease therapeutics platform.
Orphan Diseases, Renal Disease, Hepatic Disease, Specialty Pharma, and Clinical Development
Official leadership disclosure, Official Stockholm address disclosure, Specialty-pharma platform claim
Calliditas Therapeutics is published because official company materials confirm current leadership, Stockholm operating address, and a real orphan-disease therapeutics platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Stockholm, Sweden
Calliditas Therapeutics
Orphan Diseases, Renal Disease, Hepatic Disease, Specialty Pharma, and Clinical Development · Clinical-stage specialty-pharma platform
Calliditas Therapeutics runs orphan drug development, clinical program development, and commercialization readiness in Stockholm, Sweden.
- Lead
- Renee Aguiar-Lucander (verified ↗)
- Address
- Calliditas Therapeutics AB, D5, Kungsbron 1, SE-111 22 Stockholm, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 21 Mar 2026 (2mo ago)
- Scale
- Clinical-stage specialty-pharma platform
- Capabilities
- Orphan Drug Development · Clinical Program Development · Commercialization Readiness
- Founded
- 2004
- Headcount
- 51-200
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Renee Aguiar-Lucander
CEO
Full addressCalliditas Therapeutics AB, D5, Kungsbron 1, SE-111 22 Stockholm, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official Calliditas contact page listing the Stockholm office address.
Open sourceClinical-stage specialty-pharma platform
Stockholm, Sweden. Orphan Diseases, Renal Disease, Hepatic Disease, Specialty Pharma, and Clinical Development. Review completed on 21 Mar 2026.
Swedish corporate and pharmaceutical-development oversight
Official leadership disclosure, Official Stockholm address disclosure, Specialty-pharma platform claim
Orphan Diseases, Renal Disease, Hepatic Disease, Specialty Pharma, and Clinical Development
Calliditas Therapeutics is published because official company materials confirm current leadership, Stockholm operating address, and a real orphan-disease therapeutics platform.
Editorial note
Calliditas Therapeutics is published because official company materials confirm current leadership, Stockholm operating address, and a real orphan-disease therapeutics platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Orphan Drug Development
Clinical Program Development
Commercialization Readiness
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Clinical development workflow
Regulatory-commercial infrastructure
Therapeutics portfolio systems
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
21 Mar 2026: Executive identity confirmed via official management disclosure.
21 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Calliditas Therapeutics located?
- Calliditas Therapeutics operates from Calliditas Therapeutics AB, D5, Kungsbron 1, SE-111 22 Stockholm, Sweden, Stockholm, Sweden.
- Who runs Calliditas Therapeutics?
- Calliditas Therapeutics is led by Renee Aguiar-Lucander, CEO. Verified 21 Mar 2026.
- What does Calliditas Therapeutics do?
- Calliditas Therapeutics runs orphan drug development, clinical program development, and commercialization readiness in Stockholm, Sweden. Core capabilities: Orphan Drug Development, Clinical Program Development, Commercialization Readiness.
Editorial context
Related technical briefs
Briefs that name Stockholm as a covered market or city.